Keywords: new, data, arixtra, treatment, pe, once-daily, subcutaneous
New data for Arixtra in treatment of PE
Article | 10 November 2003
Once-daily subcutaneous administration of AkzoNobel/Sanofi-Synthelabo's Arixtra (fondaparinux) is at least as effective and safe as intravenous unfractionated heparin (UFH) ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- SciClone gains China rights to Zensun's Neucardin
